| Código de ensayo | Título del ensayo | Estado | Tipo de ensayo | Situación clínica | Centro |
|---|---|---|---|---|---|
| POLARIS-2 | A global multicenter, open label, randomized, phase 3 registrational study of olverembatinib (hqp1351) in patients with chronic phase chronic myeloid leukemia (polaris-2) | Abierto a inclusión | Ensayo de Fase III | Hospital Universitario 12 de Octubre (Madrid) |
|
| CLL18 / MOIRAI | A phase 3 multicenter, randomized, prospective, open-label trial of fixed-duration (12 months) venetoclax/obinutuzumab vs. Fixed-duration (15 months) venetoclax/pirtobrutinib vs. Mrd-guided venetoclax/pirtobrutinib in patients with previously untreated chronic lymphocytic leukemia (cll)/small lymphocytic lymphoma (sll) aiming to establish measurement of individual residual disease for adaption of treatment duration to improve outcome. (moirai) | Abierto a inclusión | Ensayo de Fase III | Hospital Universitario 12 de Octubre (Madrid) |
